213 related articles for article (PubMed ID: 32707054)
1. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Profiling of Conjunctival Melanocytic Intraepithelial Lesions, Including SOX10, HMB45, Ki67, and P16.
Milman T; Zhang Q; Ang S; Elder D; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Am J Ophthalmol; 2021 Feb; 222():148-156. PubMed ID: 33002486
[TBL] [Abstract][Full Text] [Related]
3. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
4. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
Garola R; Singh V
Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of benign and malignant melanocytic lesions of the conjunctiva using double-staining.
Soon AK; Brownstein S; Tang T; Saleh S; Jiang K; Levac J; Blanco P; Farmer J
Can J Ophthalmol; 2019 Dec; 54(6):699-707. PubMed ID: 31836103
[TBL] [Abstract][Full Text] [Related]
7. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
9. Use of p16 immunohistochemical stain to help differentiate inflamed melanocytic nevi from metastatic melanoma in the setting of immunotherapy.
Adelman M; Lyons AB; Seale L; Friedman BJ
J Am Acad Dermatol; 2020 Apr; 82(4):e117-e119. PubMed ID: 31765681
[No Abstract] [Full Text] [Related]
10. A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.
Uguen A; Talagas M; Costa S; Duigou S; Bouvier S; De Braekeleer M; Marcorelles P
Diagn Pathol; 2015 Oct; 10():195. PubMed ID: 26503349
[TBL] [Abstract][Full Text] [Related]
11. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
12. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
13. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
[TBL] [Abstract][Full Text] [Related]
14. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
15. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunohistopathological study of conjunctival melanocytic lesions in pediatric and adolescent patients. A case series.
Bogdănici CM; Costea CF; Dumitrescu GF; Sava A; Ciobanu Apostol DG; Scripcariu DV; Nicoară SD; Tănase DM; Andriescu EC; Cărăuleanu A; Danciu M; Sălăvăstru SC; Schmitzer S; Cucu AI; Niagu IA
Rom J Morphol Embryol; 2021; 62(4):907-915. PubMed ID: 35673810
[TBL] [Abstract][Full Text] [Related]
17. Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva.
Pache M; Glatz-Krieger K; Sauter G; Meyer P
Graefes Arch Clin Exp Ophthalmol; 2006 Jan; 244(1):113-7. PubMed ID: 16003514
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical profiling including beta-catenin in conjunctival melanocytic lesions.
Reddy HS; Keene CD; Chang SH; Jian-Amadi A; Cimino PJ
Exp Mol Pathol; 2017 Apr; 102(2):198-202. PubMed ID: 28161440
[TBL] [Abstract][Full Text] [Related]
19. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
[TBL] [Abstract][Full Text] [Related]
20. A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors.
Redon S; Guibourg B; Talagas M; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2018; 26(10):714-720. PubMed ID: 28362709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]